Singapore markets closed

Straits Times Index
3,331.70
+5.42(+0.16%)
S&P 500
5,462.84
-6.46(-0.12%)
Dow
38,952.62
-159.54(-0.41%)
Nasdaq
17,740.81
+23.16(+0.13%)
Bitcoin USD
61,728.67
+699.53(+1.15%)
CMC Crypto 200
1,278.72
-5.07(-0.39%)

ITCI Jan 2025 100.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.4000

0.0000

(0.00%)

As of 03:10PM EDT. Market open.

Zacks
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zacks
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.